Codexis, Inc. (Nasdaq:CDXS), a developer of industrial enzymes to enable the production of biofuels, biobased chemicals, and pharmaceutical intermediates, today announced it has been awarded a key patent from the U.S. Patent and Trademark Office covering an important component of the company’s proprietary enzymatic technology that can be used for production of cellulosic biofuels.
Codexis specifically received U.S. Patent No. 8,143,050, “Recombinant Beta-Glucosidase Variants for Production of Soluble Sugars from Cellulosic Biomass”.
“This patent covers an enzyme group essential in the conversion of cellulosic biomass to fermentable sugars, which can subsequently be used for the production of a wide range of cellulosic biofuels,” said Peter Strumph, Interim Chief Executive Officer. “This adds to the strong Codexis intellectual property portfolio already in place and further strengthens the competitive position in the biofuels market for both Codexis and Shell, our advanced biofuels development partner.”
This is the latest patent to be added to the company’s portfolio of intellectual property which also includes patents covering the company’s CodeXyme™ Cellulase Enzymes and CodeEvolver™ directed evolution technology platform, among others.
About Codexis, Inc.
Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, biobased chemicals and pharmaceutical intermediates. Codexis’ product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see
This press release contains forward-looking statements relating to the Codexis intellectual property portfolio and the patent on biofuels technology referred to in this press release. Important factors that could cause actual results to differ materially from the forward-looking statements in this press release include risks that we may not be able to enforce our intellectual property rights and that we may not be able to compete if we lose some of our intellectual property rights. Additional factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2012, including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.